

## DAFTAR PUSTAKA

- Aldeyab, M.A., Harbarth, S., Vernaz, N., Kearney, M.P., Scott, M.G., Darwish Elhajji, F.W., dkk., 2012. The impact of antibiotic use on the incidence and resistance pattern of extended-spectrum beta-lactamase-producing bacteria in primary and secondary healthcare settings: The impact of antibiotic use on the incidence and resistance pattern of ESBLs. *British Journal of Clinical Pharmacology*, **74**: 171–179.
- Alekshun, M.N. dan Levy, S.B., 2007. Molecular Mechanisms of Antibacterial Multidrug Resistance. *Cell*, **128**: 1037–1050.
- Alyamani, E.J., Khiyami, A.M., Booq, R.Y., Majrashi, M.A., Bahwerth, F.S., dan Rechkina, E., 2017. The occurrence of ESBL-producing *Escherichia coli* carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia. *Annals of Clinical Microbiology and Antimicrobials*, **16**: 1–13.
- Amábile-Cuevas, C.F., 2007. *Antimicrobial Resistance in Bacteria*. Horizon Scientific Press.
- Anonim, 2018. 'Defined Daily Dose (DDD)', WHO. URL: [http://www.who.int/medicines/regulation/medicines-safety/toolkit\\_ddd/en/](http://www.who.int/medicines/regulation/medicines-safety/toolkit_ddd/en/) (diakses tanggal 16/1/2018).
- Bell, J.M., Turnidge, J.D., Gales, A.C., Pfaller, M.A., Jones, R.N., dan Group, S.A.S., 2002. Prevalence of extended spectrum  $\beta$ -lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99). *Diagnostic microbiology and infectious disease*, **42**: 193–198.
- Bhusal, Y., Mihu, C.N., Tarrand, J.J., dan Rolston, K.V., 2011. Incidence of Fluoroquinolone-Resistant and Extended-Spectrum  $\beta$ -Lactamase-Producing *Escherichia coli* at a Comprehensive Cancer Center in the United States. *Chemotherapy*, **57**: 335–338.
- Bonnet, R., 2004. Growing Group of Extended-Spectrum -Lactamases: the CTX-M Enzymes. *Antimicrobial Agents and Chemotherapy*, **48**: 1–14.
- Bradford, P.A., 2001. Extended-Spectrum -Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. *Clinical Microbiology Reviews*, **14**: 933–951.

- Bramantono, Purwati, dan Hamidah, 2013. 'The Prevalence of Extended Spectrum Beta-Lactamase (ESBL) In Third Generation Cephalosporin Usage Among Sepsis Patients In The Department Of Internal Medicine RSUD Dr. Soetomo Surabaya', . *Folia Medica Indonesiana*, **49** (4): 244–251.
- Chakraborty, S., 2016. Prevalence, antibiotic susceptibility profiles and ESBL production in *Klebsiella pneumoniae* and *Klebsiella oxytoca* among hospitalized patients. *Periodicum Biologorum*, **118**: 53–58.
- Chaudhary, U. dan Aggarwal, R., 2004. Extended spectrum-lactamases (ESBL)-An emerging threat to clinical therapeutics. *Indian Journal of Medical Microbiology*, **22**: 75.
- De Champs, C., Rouby, D., Guelon, D., Sirot, J., Sirot, D., Beytout, D., dkk., 1991. A case-control study of an outbreak of infections caused by *Klebsiella pneumoniae* strains producing CTX-1 (TEM-3) beta-lactamase. *Journal of Hospital Infection*, **18**: 5–13.
- Dhillon, R.H.-P. dan Clark, J., 2012. ESBLs: A Clear and Present Danger? *Critical Care Research and Practice*, **2012**: 1–11.
- Du, B., Long, Y., Liu, H., Chen, D., Liu, D., Xu, Y., dkk., 2002. Extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* bloodstream infection: risk factors and clinical outcome. *Intensive Care Medicine*, **28**: 1718–1723.
- Ensor, V.M., Shahid, M., Evans, J.T., dan Hawkey, P.M., 2006. Occurrence, prevalence and genetic environment of CTX-M -lactamases in Enterobacteriaceae from Indian hospitals. *Journal of Antimicrobial Chemotherapy*, **58**: 1260–1263.
- Eveillard, M., Schmit, J.-L., dan Eb, F., 2002. Antimicrobial Use Prior to the Acquisition of Multiresistant Bacteria. *Infection Control & Hospital Epidemiology*, **23**: 155–158.
- Falagas, M.E. dan Karageorgopoulos, D.E., 2009. Extended-spectrum  $\beta$ -lactamase-producing organisms. *Journal of Hospital Infection*, **73**: 345–354.
- Falagas, M.E., Mourtzoukou, E.G., dan Vardakas, K.Z., 2007. Sex differences in the incidence and severity of respiratory tract infections. *Respiratory Medicine*, **101**: 1845–1863.

- Falahi, J., Khaledi, A., Alikhani, M.Y., Taghipour, A., Jamehdar, S.A., Honarmand, M., dkk., 2017. Prevalence of Nosocomial Infection in Different Wards of Ghaem Hospital, Mashhad. *Avicenna Journal of Clinical Microbiology and Infection*, **4**: e40297.
- Fillit, H., Rockwood, K., Woodhouse, K.W., dan Brocklehurst, J.C. (Editor), 2010. *Brocklehurst's Textbook of Geriatric Medicine and Gerontology*, 7th ed. ed, Expert consult. Online and print. Saunders/Elsevier, Philadelphia, PA.
- Gallagher, J.C., MacDougall, C., dan Gallagher, J.C., 2018. *Antibiotics Simplified*.
- Ghafourian, S., Sadeghifard, N., Soheili, S., dan Sekawi, Z., 2015. Extended Spectrum Beta-lactamases: Definition, Classification and Epidemiology. *Current Issues in Molecular Biology*, .
- Gupta, N., Sohanlal, T., Soman, R., Shetty, A., dan Rodrigues, C., 2011. The relevance of ESBL producing isolates in patients surgically treated for acute appendicitis. *The Journal of the Association of Physicians of India*, **59**: 293–295.
- Gutiérrez, F., Masiá, M., Mirete, C., Soldán, B., Carlos Rodríguez, J., Padilla, S., dkk., 2006. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. *Journal of Infection*, **53**: 166–174.
- Hawkey, P.M., 2008. Prevalence and clonality of extended-spectrum  $\beta$ -lactamases in Asia. *Clinical Microbiology and Infection*, **14**: 159–165.
- Hayati, Z., Rizal, S., dan Putri, R., 2017. 'Isolation of Extended-Spectrum B-lactamase (ESBL) Producing Escherichia coli and Klebsiella pneumoniae from Clinical Isolates in RSUD dr. Zainoel Abidin, Aceh', , dalam: *The 7th AIC ICMR on Health and Life Sciences*. Dipresentasikan pada The Annual International Conference 2017, Syiah Kuala University.
- Herindrainy, P., Randrianirina, F., Ratovoson, R., Hariniana, E.R., Buisson, Y., Genel, N., dkk., 29 Jul 11. Rectal Carriage of Extended-Spectrum Beta-Lactamase-Producing Gram-Negative Bacilli in Community Settings in Madagascar. *PLOS ONE*, **6**: e22738.
- Jacoby, G.A., 1994. Genetics of extended-spectrum beta-lactamases. *European Journal of Clinical Microbiology & Infectious Diseases*, **13**: S2–S11.

- Jacoby, G.A. dan Munoz-Price, L.S., 2005. The New  $\beta$ -Lactamases. *New England Journal of Medicine*, **352**: 380–391.
- Joseph, N.M., 2015. Relationship between Antimicrobial Consumption and the Incidence of Antimicrobial Resistance in *Escherichia coli* and *Klebsiella pneumoniae* Isolates. *Journal of Clinical and Diagnostic Research*, **9** (2): DC08-DC12.
- Karim, A., Poirel, L., Nagarajan, S., dan Nordmann, P., 2001. Plasmid-mediated extended-spectrum  $\beta$ -lactamase (CTX-M-3 like) from India and gene association with insertion sequence IS Ecp1. *FEMS microbiology letters*, **201**: 237–241.
- Kariuki, S., Revathi, G., Corkill, J., Kiiru, J., Mwituria, J., Mirza, N., dkk., 2007. *Escherichia coli* from community-acquired urinary tract infections resistant to fluoroquinolones and extended-spectrum beta-lactams. *The Journal of Infection in Developing Countries*, **1**: 257–262.
- Kemenkes RI, 2011. Pedoman Pelayanan Kefarmasian Untuk Terapi Antibiotik. *Kementerian Kesehatan Republik Indonesia*, .
- Kołpa, M., Wałaszek, M., Gniadek, A., Wolak, Z., dan Dobroś, W., 2018. Incidence, Microbiological Profile and Risk Factors of Healthcare-Associated Infections in Intensive Care Units: A 10 Year Observation in a Provincial Hospital in Southern Poland. *International Journal of Environmental Research and Public Health*, **15**: 112–127.
- KPMG LLP, 2014. 'The Global Economic Impact Of Antimicrobial Resistance', , *Independent review*, . a UK limited liability partnership and a member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), Swiss.
- Kuntaman, M.N. dan Usman, H., 2006. Multiresistance Pattern of Extended Spectrum B-Lactamase (Esbl)–*Escherichia coli* and *Klebsiella pneumoniae* Strains. *Folia Medica Indonesiana*, **42**: 40–46.
- Kuwabara, K., Imanaka, Y., Matsuda, S., Fushimi, K., Hashimoto, H., Ishikawa, K.B., dkk., 2008. The association of the number of comorbidities and complications with length of stay, hospital mortality and LOS high outlier, based on administrative data. *Environmental Health and Preventive Medicine*, **13**: 130–137.

- Lakshmi, R., Nusrin, K.S., Georgy, S.A., dan Sreelakshmi, K.S., 2014. Role Of Beta Lactamases In Antibiotic Resistance : A Review. *International Research Journal Of Pharmacy*, **5**: 37–40.
- Lautenbach, E., Patel, J.B., Bilker, W.B., Edelstein, P.H., dan Fishman, N.O., 2001. Extended-spectrum  $\beta$ -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. *Clinical Infectious Diseases*, **32**: 1162–1171.
- Lee, H., Jung, D., Yeom, J.S., Son, J.S., Jung, S.-I., Kim, Y.-S., dkk., 2009. Evaluation of Ceftriaxone Utilization at Multicenter Study. *The Korean Journal of Internal Medicine*, **24**: 374–380.
- Lestari, P.I., 2012. Pola Kepekaan Bakteri terhadap Antibiotik di Ruang Rawat Intensif RSPI Prof. Dr. Sulianti Saroso Jakarta 5.
- Lo, D.S., Shieh, H.H., Ragazzi, S.L.B., Koch, V.H.K., Martinez, M.B., dan Gilio, A.E., 2013. Community-acquired urinary tract infection: age and gender-dependent etiology. *Jornal Brasileiro de Nefrologia*, **35**: 93–98.
- MacKenzie, F.M. dan Gould, I.M., 2005. Quantitative Measurement of Antibiotic Use, dalam: *Antibiotic Policies*. Springer, Boston, MA, hal. 105–118.
- McDanel, J., Schweizer, M., Crabb, V., Nelson, R., Samore, M., Khader, K., dkk., 2017. Incidence of Extended-Spectrum  $\beta$ -Lactamase (ESBL)-Producing *Escherichia coli* and *Klebsiella* Infections in the United States: A Systematic Literature Review. *Infection Control & Hospital Epidemiology*, **38**: 1209–1215.
- Minardi, D., d’Anzeo, Cantoro, Conti, dan Muzzonigro, 2011. Urinary tract infections in women: etiology and treatment options. *International Journal of General Medicine*, 333.
- Nathisuwan, S., Burgess, D.S., dan Lewis, J.S., 2001. Extended-spectrum  $\beta$ -lactamases: epidemiology, detection, and treatment. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, **21**: 920–928.
- Nicolau, D.P., 2008. Carbapenems: a potent class of antibiotics. *Expert Opinion on Pharmacotherapy*, **9**: 23–37.
- Nordmann, P., Poirel, L., Walsh, T.R., dan Livermore, D.M., 2011. The emerging NDM carbapenemases. *Trends in Microbiology*, **19**: 588–595.

- O'Grady, N.P., Alexander, M., Burns, L.A., Dellinger, E.P., Garland, J., Heard, S.O., dkk., 2011. Guidelines for the Prevention of Intravascular Catheter-related Infections. *Clinical Infectious Diseases*, **52**: e162–e193.
- Parathon, H., Kuntaman, K., Widiastoety, T.H., Muliawan, B.T., Karuniawati, A., Qibtiyah, M., dkk., 2017. Progress towards antimicrobial resistance containment and control in Indonesia. *bmj*, **358**: j3808.
- Paterson, D.L. dan Bonomo, R.A., 2005. Extended-Spectrum -Lactamases: a Clinical Update. *Clinical Microbiology Reviews*, **18**: 657–686.
- Pitout, J.D. dan Laupland, K.B., 2008. Extended-spectrum  $\beta$ -lactamase-producing Enterobacteriaceae: an emerging public-health concern. *The Lancet infectious diseases*, **8**: 159–166.
- Pratt, R. dan Pellowe, C., 2010. Good practice in management of patients with urethral catheters. *Nursing Older People*, **22**: 25–29.
- Quale, J.M., Landman, D., Bradford, P.A., Visalli, M., Ravishankar, J., Flores, C., dkk., 2002. Molecular epidemiology of a citywide outbreak of extended-spectrum  $\beta$ -lactamase-producing *Klebsiella pneumoniae* infection. *Clinical infectious diseases*, **35**: 834–841.
- Ramphal, R. dan Ambrose, P.G., 2006. Extended-spectrum  $\beta$ -lactamases and clinical outcomes: current data. *Clinical infectious diseases*, **42**: S164–S172.
- Rawat, D. dan Nair, D., 2010. Extended-spectrum  $\beta$ -lactamases in gram negative bacteria. *Journal of Global Infectious Diseases*, **2**: 263–274.
- Rice, L.B., Eckstein, E.C., DeVente, J., dan Shlaes, D.M., 1996. Ceftazidime-resistant *Klebsiella pneumoniae* isolates recovered at the Cleveland department of Veterans Affairs Medical Center. *Clinical infectious diseases*, **23**: 118–124.
- Roh, K.H., Uh, Y., Kim, J.-S., Kim, H.-S., Shin, D.H., dan Song, W., 2008. First Outbreak of Multidrug-Resistant *Klebsiella pneumoniae* Producing both SHV-12-Type Extended-Spectrum  $\beta$ -Lactamase and DHA-1-Type AmpC  $\beta$ -Lactamase at a Korean Hospital. *Yonsei Medical Journal*, **49**: 53–57.
- Santajit, S. dan Indrawattana, N., 2016. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. *BioMed Research International*, **2016**: 1–8.



- Shaikh, S., Fatima, J., Shakil, S., Rizvi, S.M.D., dan Kamal, M.A., 2015. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi Journal of Biological Sciences*, **22**: 90–101.
- Skrlin, Bacic Vrca, V., Marusic, S., Ciric-Crncec, M., dan Mayer, L., 2011. Impact of Ceftriaxone De-restriction on the Occurrence of ESBL-Positive Bacterial Strains and Antibiotic Consumption. *Journal of Chemotherapy*, **23**: 341–344.
- Sougakoff, W., Goussard, S., Gerbaud, G., dan Courvalin, P., 1988. Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes. *Clinical Infectious Diseases*, **10**: 879–884.
- Stryjewski, M.E. dan Boucher, H.W., 2009. Gram-negative bloodstream infections. *International Journal of Antimicrobial Agents*, **5**.
- Tham, J., Odenholt, I., Walder, M., Melander, E., dan Andersson, L., 2013. Risk factors for infections with extended- spectrum beta-lactamase-producing *Escherichia coli* in a county of Southern Sweden. *Infection and Drug Resistance*, **6**: 93–97.
- Tumbarello, M., Trecarichi, E.M., Bassetti, M., De Rosa, F.G., Spanu, T., Di Meco, E., dkk., 2011. Identifying Patients Harboring Extended-Spectrum- $\beta$ -Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System. *Antimicrobial Agents and Chemotherapy*, **55**: 3485–3490.
- WHOCC, 2018. 'ATC/DDD Index', . URL: [https://www.whocc.no/atc\\_ddd\\_index/?code=J](https://www.whocc.no/atc_ddd_index/?code=J) (diakses tanggal 17/1/2018).
- World Health Organization, 2003. *Introduction to Drug Utilization Research*. WHO, Oslo, Norway.
- World Health Organization (Editor), 2014. *Antimicrobial Resistance: Global Report on Surveillance*. World Health Organization, Geneva, Switzerland.
- World Health Organization, W., 2018. 'Guidelines for ATC classification and DDD assignment', . URL: [https://www.whocc.no/atc\\_ddd\\_index\\_and\\_guidelines/guidelines/](https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/) (diakses tanggal 16/1/2018).